(MENAFN- GlobeNewsWire - Nasdaq) itemprop="articleBody">
PRESS RELEASE
December 13, 2018
The Annual General Meeting on May 24, 2018, resolved that a Nomination Committee shall be appointed before coming election and remuneration. The Nomination Committee shall comprise three members, which should be representative for the two largest shareholders as of last September, together with the Chairman of the Board of Directors.
On September 30, 2018, the two largest shareholders, which desired to appoint a representative to the Nomination Committee, were Jørgen Drejer and Thomas Feldthus. Each such shareholder has appointed a representative, as shown below, who together with the Chairman of the Board of Directors will form Saniona AB's Nomination Committee.
The Nomination Committee's member are:
Søren Skjærbæk, Partner at Ursus law firm, Vejle, Denmark, appointed by Jørgen Drejer John Haurum, professional board member for life science companies and former CEO of F-star Biotechnology Limited, Cambridge, UK, appointed by Thomas Feldthus J. Donald deBethizy, Chairman of Saniona AB's Board The Nomination Committee shall prepare and submit proposals to the Annual General Meeting 2019 regarding:
election of the Chairman at the Annual General Meeting election of the Chairman and other members of the Board; remuneration for the Chairman and for each of the other members of the Board and, if applicable, remuneration for committee work; election of the auditor and the auditor's remuneration; and principles for appointing the Nomination Committee. The instruction and charter for the Nomination Committee in Saniona AB can be found in the Corporate Governance section at the company's website, For more information, please contact
Thomas Feldthus, EVP and CFO, Saniona, Mobile: +45 2210 9957, E-mail:
The information was submitted for publication, through the agency of the contact person set out above, at 08:00 CET on December 13, 2018.
About Saniona
Saniona is a research and development company focused on drugs for diseases of the central nervous system and metabolic disorders. The company has four programs in clinical development. Saniona intends to develop and commercialize treatments for orphan indications such as Prader-Willi syndrome and hypothalamic obesity on its own. The research is focused on ion channels and the company has a broad portfolio of research programs. Saniona has partnerships with Boehringer Ingelheim GmbH, Productos Medix, S.A de S.V and Cadent Therapeutics. Saniona is based in Copenhagen, Denmark, and the company's shares are listed at Nasdaq Stockholm Small Cap (OMX: SANION). Read more at .
Attachment
20181213 - PR - Nomination Committee - UK MENAFN1312201800703653ID1097824512
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.